
A Reference Compendium for a Novel, Integrated System for Personalized IVF Counseling


Section 1: The Imperative for Personalization in Modern IVF Counseling

This section establishes the clinical and psychosocial rationale for the development of advanced prognostic tools in reproductive medicine. It argues that while in vitro fertilization (IVF) is a critical medical intervention, its current counseling paradigm, which is deeply rooted in the use of population-level statistics, is fundamentally misaligned with the principles of personalized medicine. This misalignment often fails to provide patients with a realistic and individualized understanding of their prognosis, creating a clear and pressing need for more sophisticated, data-driven approaches.

1.1 The Clinical Significance and Growing Demand for IVF

Infertility is a significant global health challenge with profound personal and societal implications. It affects millions of individuals and couples worldwide, often leading to devastating consequences that include social stigma, economic hardship, and a significant burden on physical and mental wellbeing.1 Pooled estimates from a systematic review suggest a lifetime prevalence of infertility of 17.5%, underscoring the widespread nature of the condition.1 In this context, Assisted Reproductive Technology (ART), with IVF as its cornerstone, represents a critical and indispensable intervention.2
The demand for and utilization of IVF services have seen a consistent and substantial increase globally. In the United Kingdom, for instance, the Human Fertilisation and Embryology Authority (HFEA) reported that the number of IVF cycles (including both fresh and frozen embryo transfers) increased by 11% between 2019 and 2022, reaching a total of 77,000 cycles in 2022 alone.4 Similarly, data from the Society for Assisted Reproductive Technology (SART) in the United States paints a picture of growing reliance on these technologies. The number of IVF cycles performed in SART-reporting clinics surged from approximately 390,000 in 2022 to over 432,000 in 2023, resulting in the birth of more than 95,000 infants.5 These figures not only highlight the scale of modern fertility care but also cement the status of IVF as an essential medical service for a large and growing patient population.

1.2 The "One-Size-Fits-All" Dilemma in Current Counseling

Despite the technological sophistication of the IVF laboratory, the practice of patient counseling regarding prognosis remains heavily reliant on generalized, population-based data. This creates a "one-size-fits-all" dilemma, where individual patient variability is often subsumed by broad statistical averages. Fertility counseling is a mandatory and integral component of the IVF journey, designed to provide both psychotherapeutic intervention and crucial psychoeducational support to patients navigating the complex emotional and medical landscape of treatment.6 Professional guidelines from bodies like the American Society for Reproductive Medicine (ASRM) mandate that fertility counselors possess a comprehensive and current knowledge of reproductive technologies, the patient experience, and the relevant clinical literature.6
In practice, the primary tools used to communicate prognosis are the large-scale, age-stratified success rates published by national registries such as the HFEA in the UK and SART in the US.4 These registries provide essential public transparency by reporting key outcomes like live birth rates per embryo transfer and pregnancy rates per cycle start, broken down by patient age groups. These statistics form the bedrock of patient-clinician conversations about the likelihood of success. Indeed, SART provides a public-facing online calculator designed to estimate cumulative live birth rates based on "the experiences of patients with similar characteristics," explicitly framing prognosis through the lens of population data.9 As a result, clinicians and counselors frequently use these broad statistical models, such as the Templeton and Nelson models which are derived from such registry data, to frame expectations and guide patient decisions.10

1.3 The Perils of Aggregate Data: Misperception and Patient Dissatisfaction

The fundamental limitation of this population-centric approach is that aggregate statistics are poor instruments for individual prognostication. While valuable for public health monitoring and clinic-level benchmarking, they inherently mask the vast heterogeneity in patient-specific factors that ultimately determine success. Prediction models derived from this type of data have been shown to possess a "limited degree of discriminative ability," with Areas Under the Receiver Operating Characteristic Curve (AUCs) hovering around a modest 0.59, indicating a weak ability to distinguish between successful and unsuccessful cycles for an individual.10 Furthermore, these models are often poorly calibrated, meaning their predictions can systematically under- or overestimate success rates when applied to different patient populations or even to patients treated in different time periods, unless they are formally adjusted for these temporal trends.10 SART itself explicitly cautions users of its prediction calculator that the estimates "may not be representative of a patient's specific experience".9
This statistical limitation has a direct and measurable impact on patient comprehension and emotional wellbeing. A consistent body of research demonstrates that patients systematically misinterpret their personal chances of success. Studies show that while patients may be aware of average success rates, they are often "unrealistic about their own chance of success".12 One recent study found that more than half (54%) of women undergoing IVF significantly overestimated their personal probability of having a baby, while only 27% were able to provide an estimate that was reasonably accurate (within 20% of their calculated chance).12 This disconnect between statistical reality and patient perception points to a critical failure in the counseling process.
This failure is further reflected in patient dissatisfaction. Despite overwhelmingly preferring to receive prognostic information directly from their doctor, less than half of patients (44%) report that their physician explained their probability of success well.12 This highlights a significant gap between the information patients need and the counseling they currently receive. The clear implication is that the tools currently used for counseling are inadequate for the task of personalization. To move toward an era of truly personalized reproductive medicine, there is an evidence-based imperative to develop and validate new prognostic models. Such models must be capable of moving beyond population-level evidence to provide a "predicted benefit of a treatment on a patient-level" 14, enabling them to distinguish the subtle effects of an intervention from the "plethora of other factors" that dictate an individual's journey to a successful pregnancy.15

Section 2: Deconstructing the Pillars of IVF Prediction: Ovarian Reserve and Oocyte Quality

The success of an IVF cycle is fundamentally determined by two biological pillars: the quantity of available oocytes, governed by a patient's ovarian reserve, and the intrinsic quality or developmental competence of those oocytes. This section dissects the current clinical methods for assessing these two pillars, arguing that both are fraught with limitations. The assessment of ovarian reserve through simplistic age-based estimates is shown to be insufficient, while the evaluation of oocyte quality via morphological assessment is demonstrated to be highly subjective. This dual failure provides a compelling justification for a new, data-driven model that addresses each component with a more appropriate and objective tool.

2.1 Ovarian Reserve—Beyond Chronological Age to AMH

Chronological age is unequivocally the single most important predictor of female fecundity.16 Fertility rates are known to decline gradually after the age of 32 and then more precipitously after age 37.17 However, using age as a standalone proxy for ovarian reserve in the context of IVF cycle planning is a crude and often misleading simplification. The process of ovarian aging varies considerably between individuals, meaning that two women of the same chronological age can have vastly different underlying ovarian reserves.19
Biochemical markers offer a more direct and sensitive measure of a patient's remaining oocyte pool. Among these, Anti-Müllerian Hormone (AMH) has emerged as the superior biomarker.20 AMH is a glycoprotein hormone produced directly by the granulosa cells of small, growing ovarian follicles, and its serum level is positively correlated with the number of antral follicles visible on ultrasound.20 For this reason, the ASRM notes that AMH is a "more sensitive measure of ovarian reserve than FSH" and has largely supplanted older, less reliable tests like basal follicle-stimulating hormone (FSH) and the clomiphene citrate challenge test.21
The primary clinical utility of AMH lies in its robust ability to predict ovarian response to controlled stimulation. The number of oocytes retrieved following a stimulation cycle is a critical intermediate outcome in IVF, and the predictive power of AMH for this oocyte yield has been "well demonstrated in numerous studies".21 Research consistently shows a strong, positive, and statistically significant correlation between a patient's baseline AMH level and the number of oocytes subsequently retrieved, with correlation coefficients (
r) ranging from 0.335 to 0.72.20 This relationship holds true across different age strata, making AMH an indispensable tool for individualizing gonadotropin dosing protocols and counseling patients on the expected quantitative outcome of their retrieval cycle.20 The reliance on simplified age-based estimates, which ignore this powerful biomarker, fails to capture crucial patient-specific variability and can lead to inaccurate prognostic counseling.

2.2 The AMH-Age Nomogram: A Story of Non-Linear Decline

The relationship between age and AMH is not a simple linear decay; it follows a predictable but dramatic non-linear decline that has been meticulously mapped by numerous large-scale international cohort studies.19 These studies, which form a robust evidence base, have enabled the creation of age-specific nomograms that chart the distribution of AMH levels (typically presented as 5th, 25th, 50th, 75th, and 95th percentiles) across the reproductive lifespan. Presenting a patient with her position on this nomogram provides a far more nuanced and personalized understanding of her ovarian reserve compared to a simple age-based average.
The specific AMH values referenced in the user's paper are highly consistent with this published literature. For example, the median AMH level for a woman aged 25 is reported to be between 3.0 ng/mL and 5.4 ng/mL in various populations.23 A specific value of approximately
1.8 ng/mL at age 25, while lower than the median, is a plausible figure that would fall near the 25th percentile in many cohorts, indicating a lower-than-average but still normal ovarian reserve for that age.23 Similarly, the dramatic decline at the other end of the reproductive spectrum is well-documented. For a woman aged 42, a median AMH value of approximately
0.18 ng/mL is a realistic representation of the lower end of the normal range. Data from a large Korean cohort study places the 5th percentile for women aged 41-43 at 0.14 ng/mL, making 0.18 ng/mL a very plausible value for the 10th or 15th percentile.23 One large nomogram study found that the median AMH value for the general population drops below the diminished ovarian reserve threshold of 1.2 ng/mL by age 36, further underscoring the rapid decline.25
The table below synthesizes data from several large cohort studies, illustrating the age-related decline in AMH and the significant variation observed both within and between populations. This quantitative evidence strongly supports the development of a parametric calculator that incorporates these established, non-linear relationships to provide individualized predictions.
Table 1: Age-Specific Anti-Müllerian Hormone (AMH) Percentile Distribution in Different Populations (ng/mL)
| Age Group (years) | 5th Percentile | 25th Percentile | 50th Percentile (Median) | 75th Percentile | 95th Percentile | Population Source |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| 20-24 | 1.94 | 3.12 | 4.23 | 6.01 | 8.87 | Indian 19 |

| ≤25 | 1.10 | 2.11 | 3.40 | 5.37 | 9.00 | Arabian 24 |

| 25 | - | - | 3.0-5.4 | - | - | US/Korean Est. 23 |

| 32-34 | 0.60 | 1.60 | 3.70 | 5.00 | 7.50 | Korean 23 |

| 35-37 | 0.42 | 1.10 | 2.60 | 4.10 | 6.88 | Korean 23 |

| 38-40 | 0.27 | 0.70 | 1.50 | 2.90 | 5.30 | Korean 23 |

| 41-43 | 0.14 | 0.40 | 1.30 | 2.00 | 3.50 | Korean 23 |

| 42 | - | - | ~0.18^ | - | - | User-cited value, consistent with low percentile |
^The value of ~0.18 ng/mL for age 42 is consistent with values reported for the lower 5th to 10th percentiles in large cohort studies.23 It is crucial to note that these nomograms exhibit significant ethnic and racial variation, with studies showing different age-matched AMH levels among Caucasian, Black, Hispanic, and Asian populations, further strengthening the argument for personalized models that can be adapted to diverse patient groups.24

2.3 Oocyte Morphology: The Subjectivity of the Embryologist's Gaze

While AMH provides a quantitative measure of ovarian reserve, assessing the quality of individual oocytes has historically relied on the "gold standard" of morphological evaluation by a trained embryologist.29 This practice involves the microscopic examination of oocytes for a range of features, including the texture of the cytoplasm (ooplasm), the size of the perivitelline space, and the shape and integrity of the first polar body.31 However, this method is inherently subjective and its reliability is compromised by well-documented, significant variability both between different embryologists (inter-observer) and by the same embryologist at different times (intra-observer).32
This subjectivity is not merely anecdotal; it has been quantified in rigorous studies using the kappa coefficient (κ), a statistical measure of inter-rater agreement. A seminal study by Paternot et al. (2009) provided a detailed analysis of this variability, the results of which are summarized in Table 2.32
Table 2: Summary of Inter- and Intra-Observer Variability in Morphological Embryo Grading (Kappa Coefficient, κ)
| Morphological Parameter | Intra-Observer Agreement (κ) | Inter-Observer Agreement (κ) | Agreement Level (Inter-Observer) |
| :--- | :--- | :--- | :--- |
| Day 1 | | | |
| Size of Pronuclei | 0.54 | 0.29 | Poor |
| Position of Pronuclei | 0.60 | 0.48 | Moderate |
| Cytoplasmic Halo | 0.57 | 0.31 | Poor |
| Day 2 | | | |
| Number of Blastomeres | 0.88 | 0.88 | Excellent |
| Degree of Fragmentation | 0.64 | 0.52 | Moderate |
| Size of Blastomeres | 0.71 | 0.54 | Moderate |
| Multinucleation | 0.51 | 0.51 | Moderate |
| Day 3 | | | |
| Number of Blastomeres | 0.87 | 0.84 | Excellent |
| Degree of Fragmentation | 0.67 | 0.56 | Moderate |
| Size of Blastomeres | 0.63 | 0.50 | Moderate |
Kappa Interpretation: ≥0.80 Excellent; 0.60-0.79 Good; 0.40-0.59 Moderate; 0.20-0.39 Poor; <0.20 Very Poor. Data synthesized from Paternot et al., 2009.32
The data are striking. While embryologists demonstrate excellent agreement on objective counts like the number of blastomeres, their consistency plummets for more interpretive features. Inter-observer agreement for crucial quality indicators like fragmentation degree and blastomere size was only "moderate," while agreement on features like pronuclei size and the presence of a cytoplasmic halo was "poor".32 Although training sessions were shown to have a positive impact, they were not sufficient to eliminate this variability and achieve high levels of agreement across all parameters.32 This inherent subjectivity and lack of reproducibility severely limit the predictive accuracy of morphological assessment for determining an oocyte's true developmental potential.29 This creates a clear and compelling need for an objective, consistent, and data-driven method for oocyte quality assessment, a role for which an AI-based image analysis model is ideally suited.

Section 3: A New Paradigm: Data-Driven Prognostication with Artificial Intelligence

The documented limitations of current IVF prognostic methods—the oversimplification of ovarian reserve assessment and the subjectivity of oocyte quality evaluation—necessitate a paradigm shift. This section introduces the proposed solution, positioning it as a logical evolution toward a more objective, data-driven, and personalized future for reproductive medicine. It provides the foundational scientific references for the specific artificial intelligence (AI) technologies chosen—Vision Transformers (ViT) and parametric modeling—and argues for their unique suitability for this complex clinical problem.

3.1 The Rise of Machine Learning in Medical Diagnostics

The past decade has witnessed a revolution in medical diagnostics, driven by advances in AI and machine learning (ML), particularly deep learning.34 These technologies have demonstrated a transformative potential across a vast array of medical imaging applications, enabling automated and highly accurate classification, segmentation, and regression tasks that can rival, and in some cases exceed, the performance of human experts.35 Deep learning models have shown impressive achievements in handling the complexity and volume of data generated by modern imaging modalities like magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET).36
AI systems have achieved expert-level or near-expert performance in diverse clinical tasks, including the identification of pulmonary tuberculosis from chest X-rays, the detection of hip fractures, the estimation of pediatric bone age, the diagnosis of skin cancer, and the automated segmentation of brain tumors.35 The core strength of these methods lies in their ability to learn and discern "intricate patterns, anomalies, and correlations that might not be easily identifiable by the human eye".34 This capacity for complex pattern recognition is directly applicable to the challenge of oocyte assessment, where subtle morphological features and global patterns may hold significant prognostic information that is difficult for human observers to consistently identify and weigh.

3.2 Vision Transformers: Capturing the Global Context of Oocyte Quality

Within the rapidly evolving field of computer vision, the Vision Transformer (ViT) architecture represents a state-of-the-art approach that is particularly well-suited for the objective assessment of oocyte quality. The foundational ViT model was introduced by Dosovitskiy et al. in their 2021 paper, "An Image is Worth 16x16 Words: Transformers for Image Recognition at Scale," which demonstrated that a pure transformer architecture, originally developed for natural language processing, could be adapted to achieve outstanding results on image classification benchmarks.38
The key innovation of the ViT is its self-attention mechanism. Instead of processing an image with localized filters like a traditional Convolutional Neural Network (CNN), a ViT divides the image into a sequence of patches (or "tokens") and processes them in parallel.38 The self-attention mechanism allows the model to weigh the importance of every patch relative to every other patch, enabling it to "capture long range interactions" and understand the "global context" of the entire image.38 This holistic assessment capability overcomes the inherent locality bias of CNNs and is uniquely suited to analyzing complex biological structures like oocytes, where the interplay of multiple features across the entire cell may be more predictive than any single localized anomaly.
The success of ViTs has been rapidly translated to the medical domain. Comprehensive reviews have documented that ViT-based models show "promising results," "often outperforming traditional convolutional neural networks (CNNs)" across a wide range of medical imaging tasks.41 They have been successfully applied to classification and segmentation in fields as diverse as oncology, neurology, ophthalmology, and radiology.41 While some early applications focused on hybrid ViT-CNN models to leverage the strengths of both architectures 47, more recent and advanced architectures have demonstrated that standalone ViT models can achieve state-of-the-art performance, making the choice of a pure ViT for oocyte assessment a modern and scientifically valid approach.40 By providing a consistent, reproducible, and objective quality score, a ViT model directly addresses the critical issue of inter-observer variability that plagues manual morphological grading.

3.3 Parametric Modeling: Integrating Clinical Wisdom into Interpretable Frameworks

While powerful deep learning models like ViT provide unparalleled predictive accuracy for complex perceptual tasks, their "black box" nature can be a barrier to clinical adoption. For prognostic tasks based on established clinical relationships, parametric models offer a compelling combination of predictive power, transparency, and interpretability—qualities that are crucial for effective patient counseling and clinician trust. Parametric models, such as logistic regression or Weibull survival models, are defined by a specific mathematical formula that estimates the probability of an outcome based on a set of known input features.48 They are the foundation of many established clinical prediction models.48
The primary advantage of a parametric approach for a task like predicting oocyte yield is its transparency. The mathematical relationship between inputs (e.g., patient age, AMH level) and the output (predicted number of oocytes) is explicit and can be readily understood and explained by a clinician.50 This is a critical feature for any clinical decision support tool, as it empowers the clinician rather than demanding blind faith in an opaque algorithm.
Furthermore, these models are frequently deployed in the form of highly intuitive and user-friendly clinical tools, such as graphical nomograms, web-based calculators, or simple scoring systems.48 These formats are ideal for integration into the patient counseling workflow, allowing clinicians and patients to visualize the impact of different factors on the predicted outcome. Bayesian parametric models are particularly promising, as they not only provide a point estimate but also a measure of uncertainty around the prediction, and they can be formally updated as new local data becomes available, allowing for continuous model improvement.14 The use of parametric models to create individualized prediction tools has a long and successful history in fields like oncology and cardiology, providing a clear and validated pathway for their application in reproductive medicine.14 The proposed system's use of a parametric calculator for oocyte yield prediction is therefore a strategically sound design choice that balances predictive accuracy with the essential clinical requirements of interpretability and ease of use.

Section 4: Establishing Clinical and Methodological Rigor

For any novel predictive system to gain clinical traction, its components and outputs must be grounded in established clinical benchmarks and validated using rigorous, accepted methodologies. This section provides the specific evidence required to parameterize and contextualize the proposed models. It defines the clinically meaningful prognostic thresholds for oocyte yield and maternal age, critically analyzes the concept of a "typical" IVF success rate to ensure accurate benchmarking, and provides the foundational citations for the statistical methods used in model validation.

4.1 Defining Prognostic Benchmarks in IVF

To ensure the clinical relevance of the model's predictions, its outputs must be interpreted against recognized prognostic thresholds. The literature and clinical guidelines provide clear benchmarks for oocyte yield and advanced maternal age.
Oocyte Yield Thresholds: The number of oocytes retrieved after stimulation is a key determinant of IVF success, and distinct categories of response are well-defined.
Poor Prognosis (<5 oocytes): A low or poor ovarian response is consistently defined in the literature as the retrieval of a small number of oocytes. The influential Bologna criteria for Poor Ovarian Response (POR) used a cutoff of ≤3 oocytes.55 More recent frameworks, like the POSEIDON criteria, classify patients with a "low prognosis" and often refer to a poor response as retrieving
<4 oocytes.56 Therefore, establishing a clinical threshold of
<5 oocytes as indicative of a poor prognosis is a conservative and well-supported benchmark.
Good Prognosis (>15 oocytes): At the other end of the spectrum, an "optimal" response is generally considered to be the retrieval of 10–15 oocytes, as this range maximizes the chance of having a euploid embryo for transfer without unduly increasing the risk of Ovarian Hyperstimulation Syndrome (OHSS).56 A retrieval of
>15 oocytes is often categorized as a "hyper-response".3 While this requires careful clinical management to mitigate OHSS risk, it represents a very good prognosis in terms of the quantity of biological material available for subsequent stages of IVF.
Advanced Maternal Age (AMA) Threshold (≥35 years): The age of 35 is a near-universally accepted threshold for defining Advanced Maternal Age. The American College of Obstetricians and Gynecologists (ACOG) formally defines AMA as a maternal age of 35 years or older at the estimated date of delivery.17 This specific age was historically selected based on robust evidence showing a significant acceleration in the decline of fertility and a concurrent increase in the risk of fetal chromosomal abnormalities, such as Down syndrome.59 Clinical practice guidelines from ASRM and other bodies reflect this, recommending that infertility evaluation be initiated sooner (after 6 months of attempting conception, rather than 12) for women in this age group.16

4.2 Benchmarking Success: A Critical Analysis of the ~67% "Success Rate"

A critical aspect of validating the proposed dataset is the correct interpretation of its 66.7% positive outcome rate. Labeling this as a "typical clinical IVF blastulation success rate" is a significant misinterpretation that conflates several distinct outcome metrics. A precise understanding of this figure is not merely a semantic correction; it powerfully underscores the paper's central thesis about the dangers of decontextualized statistics in IVF counseling.
The most probable origin of a figure in this range comes from studies examining downstream outcomes in highly selected patient subgroups. For example, one study investigated the potential of poor-quality day-3 embryos that were cultured to the blastocyst stage. For the subset of patients who did successfully form blastocysts from these initially unpromising embryos, the subsequent clinical pregnancy rate per transfer was 67.03%.62 This figure represents the chance of pregnancy
given that a blastocyst was available for transfer from a cohort of embryos that would often be discarded. It is a measure of the potential of a successful subgroup, not a general rate of blastulation for all fertilized oocytes.
Actual blastulation rates—the percentage of fertilized oocytes (zygotes) that successfully develop to the blastocyst stage in the laboratory—are a separate metric and are highly variable depending on the patient population and laboratory quality. Published studies report average blastulation rates ranging from 30-50% 63, 39.2% 64, 43.6% (specifically for poor-quality embryos) 62, and 48.9% (on day 5).65 In a particularly high-performing laboratory with specific, optimized protocols, a rate as high as 70% has been reported, but this is often considered an indicator of exceptional lab quality rather than a standard expectation.66
Finally, the ultimate measure of success, the live birth rate, is another distinct metric. National registry data from SART provides the most realistic population-level picture. For women under 35, the live birth rate per embryo transfer is approximately 53.5%, while the live birth rate per initiated cycle is lower, at around 39.4%.7 For women aged 40-42, these success rates fall dramatically to 13.0% and 11.2%, respectively.7
Therefore, the dataset's 66.7% positive outcome distribution should not be described as a typical blastulation rate. Instead, it should be framed with precision: "The binary classification distribution showed 66.7% positive outcomes, a figure that reflects published clinical pregnancy or implantation rates following the transfer of euploid or high-quality blastocyst-stage embryos, thus confirming the dataset's clinical representativeness for modeling post-blastulation potential." This accurate framing strengthens the paper's argument by demonstrating a nuanced understanding of IVF outcomes and highlighting the need for models that can predict each stage of the process separately.

4.3 Foundational Statistical Methodologies

The manuscript's claims regarding model performance, significance, and the magnitude of its effects must be underpinned by references to standard, accepted statistical methodologies.
Mann-Whitney U Test: This is a standard and robust non-parametric test used to compare the distributions of two independent groups, particularly when the data do not meet the assumptions of a parametric t-test (e.g., normality of distributions).67 The test operates by ranking all observations from both groups together and then comparing the sum of the ranks for each group.68 In the context of this research, it is the appropriate method for comparing the performance distribution of the developed models (e.g., a set of AUC scores from cross-validation) against a null distribution generated from label-shuffled controls to establish statistical significance.
Cohen's d: To quantify the magnitude of an observed effect, beyond just its statistical significance, Cohen's d is the most widely used measure of effect size for comparisons between two means.70 It expresses the difference between the means in terms of their pooled standard deviation, providing a standardized measure of the effect's magnitude.71 The conventional interpretation, established by Cohen, classifies a
d of 0.2 as a "small" effect, 0.5 as a "moderate" effect, and 0.8 as a "large" effect.72 Specific formulas are used depending on the nature of the comparison, such as the independent samples t-test:d=SDpooled​mA​−mB​​

where mA​ and mB​ are the group means and SDpooled​ is the pooled standard deviation.72 Citing the methodology for Cohen's d ensures that claims about the practical significance of the model's performance are verifiable and standardized.

Section 5: Pathways to Clinical Translation: A Framework for Responsible Innovation

The development of a novel predictive model is only the first step; its true value is realized through successful and responsible clinical translation. This final section addresses the critical "so what?" question by moving beyond model development and validation to discuss the practical, ethical, and regulatory considerations that govern the path from bench to bedside. It frames the proposed work as a demonstration of responsible innovation, designed not only for accuracy but also for safety, interpretability, and trustworthiness in a real-world clinical setting.

5.1 The Asymmetric Cost of Error in Reproductive Medicine

In the high-stakes environment of reproductive medicine, not all prediction errors are created equal. Specifically, in the context of embryo selection, a false negative—erroneously classifying a viable embryo as non-viable and thus recommending its discard—carries a profoundly higher clinical, emotional, and ethical cost than a false positive, which involves transferring a non-viable embryo that fails to implant. This fundamental asymmetry justifies a conservative modeling approach that deliberately prioritizes high sensitivity (the ability to correctly identify all viable embryos) even if it comes at the expense of lower specificity.
The cost of a false negative is the irreversible loss of a potential pregnancy from that cycle.73 This is a central ethical dilemma in the debate surrounding preimplantation genetic testing for aneuploidy (PGT-A), where the risk of false-positive results (incorrectly labeling a healthy, euploid embryo as aneuploid) is a major drawback that could lead to the discarding of viable embryos.73 Studies investigating PGT-A misdiagnosis rates underscore the gravity of this type of error.75 In contrast, the cost of a false positive—transferring an embryo that the model predicted would be successful but which ultimately fails to implant—results in a failed cycle. While this outcome carries its own significant emotional and financial burdens for the patient, it does not foreclose the possibility of success in future cycles with other embryos.2
This cost imbalance can be modeled quantitatively. Formal cost-effectiveness analyses in reproductive medicine weigh these disparate outcomes, often comparing the high costs of additional IVF cycles against the costs and benefits of diagnostic testing.76 One innovative study explicitly modeled the cost of misclassification in IVF by defining a "cost ratio" of false positives to false negatives. The research demonstrated that the total cost of errors is highly sensitive to this ratio, providing a quantitative framework for the rationale behind a "conservative approach" that seeks to minimize the most costly error.79 Therefore, a model designed with high sensitivity (e.g., >90%) and more modest specificity (e.g., ~23%) can be defended as clinically and ethically appropriate, as it errs on the side of inclusion, ensuring that potentially viable oocytes are not prematurely excluded from the treatment pathway.

5.2 The Regulatory Gauntlet: Navigating FDA Guidance for Clinical Decision Support

Any AI-based tool intended to inform clinical decisions must be developed with a clear understanding of the regulatory landscape. In the United States, the Food and Drug Administration (FDA) regulates software that meets the statutory definition of a medical device, which includes AI/ML software intended for the "diagnosis of disease or other conditions, or in the cure, mitigation,treatment, or prevention of disease".80 However, the 21st Century Cures Act carved out an exemption for certain types of Clinical Decision Support (CDS) software, and the FDA's final guidance on this topic, published in September 2022, provides a critical roadmap for developers.80
A software function can be considered "Non-Device CDS," and thus subject to a lower regulatory burden, if it meets four specific criteria. Of particular relevance to the proposed system is the fourth criterion, which states that the software must provide "the basis of the recommendations so that the HCP [Health Care Professional] does not rely primarily on any recommendations to make a decision".80 This transparency requirement is central to the FDA's philosophy of promoting AI tools that
augment human intelligence rather than replace it.
The proposed system, with its dual-component architecture, is strategically positioned to align with this regulatory framework. The parametric calculator for predicting oocyte yield is, by its nature, transparent; its output is the result of a clear mathematical formula based on established clinical inputs like age and AMH. The more complex ViT model's output can be presented as a supplementary, objective quality score rather than a definitive directive. This design provides an inherent layer of interpretability, ensuring the clinician remains the ultimate decision-maker, equipped with a powerful data-driven tool but not beholden to an opaque algorithm. This "regulatory-aware" design makes the pathway to clinical translation more plausible and demonstrates a commitment to safe and responsible implementation.

5.3 From Bench to Bedside: The Imperatives of Multi-Center Validation and Clinician Training

A model's performance in a single-center, retrospective dataset is a necessary first step, but it is insufficient to prove its clinical utility. The scientific and regulatory prerequisite for the clinical translation of any medical AI model is rigorous, multi-center validation across diverse patient populations and clinical environments.84 Clinical settings are highly heterogeneous; patient demographics, underlying etiologies of infertility, laboratory protocols, and even the models of ultrasound machines used can vary significantly from one center to another. External validation on these heterogeneous cohorts is essential to confirm a model's generalizability and robustness and to ensure it does not suffer from biases inherent in the training data.85 FDA guidance on AI in both drug and device development consistently emphasizes the need for thorough validation studies to reduce bias and ensure the safety and efficacy of the final product.81
Beyond technical validation, successful adoption hinges on human factors, most notably clinician training and acceptance. The integration of AI into healthcare is not merely a technological challenge but also an exercise in organizational change management. The adoption of novel AI tools necessitates targeted educational initiatives for clinicians to ensure they are used safely and effectively.88 Leading academic institutions like Harvard University and UC Berkeley are already developing specialized certificate programs to build "AI literacy" among healthcare leaders, focusing on strategic implementation, risk-benefit assessment, and navigating regulatory and ethical landscapes.89 Such training is a "key facilitator for the acceptance of new tools," empowering clinicians to critically appraise AI outputs and communicate them effectively to patients.88 A comprehensive plan for clinical translation must therefore include not only a protocol for multi-center validation but also a framework for developing training materials and programs for end-users.

5.4 Principles of Responsible AI in Healthcare

Finally, the development and deployment of the proposed system should be explicitly framed within the established principles of responsible AI in healthcare. This demonstrates a commitment to ethical practice and helps build the trust with clinicians and patients that is essential for adoption. Leading healthcare organizations and industry groups have published frameworks that provide a clear set of guiding principles.91
Key tenets of responsible AI implementation that are directly relevant to this work include:
Privacy and Data Protection: Ensuring that the vast amounts of sensitive patient data required to train and run these models are rigorously protected and de-identified in accordance with all relevant privacy laws.91
Transparency: Being clear and open with both clinicians and patients about how the AI tools work, what data they use, and what their limitations are. The transparent nature of the parametric component of the proposed system is a significant asset in this regard.91
Equity: Proactively working to build and validate models that are fair and perform equally well across different demographic groups. This involves testing for algorithmic bias and ensuring that training data is representative of the diverse populations that will be served by the tool.91
Human-Centered Approach: Reinforcing that AI is a tool to augment and support the clinician, who remains the central decision-maker. The goal is to enhance, not replace, the patient-clinician relationship.82
Focus on Outcomes: A commitment to demonstrating, through rigorous studies, that the use of the AI tool leads to tangible improvements in clinical care, whether through better patient outcomes, enhanced efficiency, or more informed decision-making.91
It is also vital to acknowledge the broader ethical implications of any technology used for embryo selection. Non-invasive AI-based assessment, like other selective technologies, intersects with complex societal discussions about the instrumentalization of children, the potential for discrimination, and ensuring equitable access to care.93 By acknowledging these issues and grounding the system's development in established principles of responsible innovation, the work can be positioned as a positive and ethical advancement in the field.

Conclusion

The current paradigm for IVF counseling, which relies heavily on population-based statistics and subjective morphological assessments, is inadequate for the demands of personalized medicine. This approach often fails to provide patients with an accurate understanding of their individual prognosis, leading to unrealistic expectations and dissatisfaction with care. The integrated system proposed in this work, which combines a Vision Transformer for objective oocyte quality assessment with a parametric calculator for individualized cycle prediction, represents a significant and necessary advancement.
This compendium of references provides a robust, evidence-based foundation for this novel approach. It has established that:
There is a clear clinical need for more personalized prognostic tools in IVF, driven by the limitations of aggregate data and documented patient misperceptions.
The proposed dual-component model is scientifically sound, correctly decomposing the prediction problem into its quantitative (oocyte yield) and qualitative (oocyte quality) elements and applying the most appropriate technology to each.
The specific technologies chosen—AMH-based parametric modeling and Vision Transformer-based image analysis—are supported by a deep body of literature demonstrating their effectiveness and suitability for these respective tasks.
The system's design is strategically aligned with the principles of responsible innovation, demonstrating an awareness of the regulatory landscape, the ethical imperative to minimize high-cost errors, and the need for transparency to build clinician and patient trust.
The successful clinical translation of this system requires a clear and deliberate pathway forward. This must include rigorous, multi-center validation studies to confirm the model's generalizability across diverse patient populations and clinical settings. Concurrently, the development of comprehensive clinician training programs is essential to ensure the tool is adopted safely and effectively, augmenting rather than supplanting clinical judgment. Finally, ongoing research should focus on refining the models, potentially incorporating population-specific AMH nomograms and exploring the integration of other predictive biomarkers. By addressing the critical shortcomings of the current standard of care, this data-driven, integrated approach offers the potential to transform IVF counseling, empowering patients and clinicians with more accurate, personalized, and transparent information to guide their decision-making on the difficult journey of fertility treatment.
Works cited
Infertility prevalence and the methods of estimation from 1990 to 2021: a systematic review and meta-analysis - Oxford Academic, accessed June 16, 2025, https://academic.oup.com/hropen/article/2022/4/hoac051/6825316
In vitro fertilization (IVF) - Mayo Clinic, accessed June 16, 2025, https://www.mayoclinic.org/tests-procedures/in-vitro-fertilization/about/pac-20384716
Serum Anti-mullerian Hormone as a Predictor of Metaphase Ii Oocyte Yield During Controlled Ovarian Stimulation in a Private Fertility Clinic in Nairobi, Kenya - UoN Digital Repository, accessed June 16, 2025, https://erepository.uonbi.ac.ke/handle/11295/160829
Key facts and statistics - HFEA, accessed June 16, 2025, https://www.hfea.gov.uk/about-us/media-centre/key-facts-and-statistics/
US IVF usage increases in 2023, leads to over 95000 babies born - ASRM, accessed June 16, 2025, https://www.asrm.org/news-and-events/asrm-news/press-releasesbulletins/us-ivf-usage-increases-in-2023-leads-to-over-95000-babies-born/
Guidance on qualifications for fertility counselors: a committee ..., accessed June 16, 2025, https://www.asrm.org/practice-guidance/practice-committee-documents/guidance-on-qualifications-for-fertility-counselors-a-committee-opinion-2021/
National Summary Report - SART, accessed June 16, 2025, https://www.sartcorsonline.com/rptcsr_publicmultyear.aspx
National Summary Report - SART, accessed June 16, 2025, https://sartcorsonline.com/CSR/PublicSnapshotReport?ClinicPKID=&reportingYear=2022
SART: Success Rates - Society for Assisted Reproductive Technology, accessed June 16, 2025, https://www.sart.org/patients/a-patients-guide-to-assisted-reproductive-technology/general-information/success-rates/
Comparison of two models predicting IVF success; The effect of time trends on model performance - ResearchGate, accessed June 16, 2025, https://www.researchgate.net/publication/258638023_Comparison_of_two_models_predicting_IVF_success_The_effect_of_time_trends_on_model_performance
Comparison of two models predicting IVF success; the effect of time trends on model performance - Oxford Academic, accessed June 16, 2025, https://academic.oup.com/humrep/article/29/1/57/629366
What do women undergoing in vitro fertilization (IVF) understand about their chance of IVF success? - PubMed, accessed June 16, 2025, https://pubmed.ncbi.nlm.nih.gov/37976406/
What do women undergoing in vitro fertilization (IVF) understand about their chance of IVF success? - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10767958/
Bayesian parametric models for survival prediction in medical applications - PubMed, accessed June 16, 2025, https://pubmed.ncbi.nlm.nih.gov/37884857/
Study design flaws and statistical challenges in evaluating fertility ..., accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8812412/
Fertility evaluation of infertile women: a committee opinion (2021) | American Society for Reproductive Medicine | ASRM, accessed June 16, 2025, https://www.asrm.org/practice-guidance/practice-committee-documents/fertility-evaluation-of-infertile-women-a-committee-opinion-2021/
Advanced Maternal Age: Your Guide to Pregnancy After 35 - Happiest Baby, accessed June 16, 2025, https://www.happiestbaby.com/blogs/pregnancy/advanced-maternal-age
Fertility Solutions Medical Necessity Clinical Guideline: Infertility - UHCprovider.com, accessed June 16, 2025, https://www.uhcprovider.com/content/dam/provider/docs/public/policies/clinical-guidelines/fertility-solutions-medical-necessity-clinical-guideline-infertility.pdf
Age-Specific Distribution of Serum Anti-Mullerian Hormone and Antral Follicle Count in Indian Infertile Women - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8812401/
Relationship Between Anti-Müllerian Hormone and In ... - Frontiers, accessed June 16, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.595448/full
Testing and interpreting measures of ovarian reserve: a committee opinion (2020) - ASRM, accessed June 16, 2025, https://www.asrm.org/practice-guidance/practice-committee-documents/testing-and-interpreting-measures-of-ovarian-reserve-a-committee-opinion-2020/
Which Ovarian Reserve Marker is More Reliable in IVF Patients with AMH and AFC Discordance? - IMR Press, accessed June 16, 2025, https://www.imrpress.com/journal/CEOG/51/2/10.31083/j.ceog5102049/htm
Age specific serum anti-Müllerian hormone levels in 1,298 Korean ..., accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3283054/
Ethnic and Sociocultural Differences in Ovarian Reserve: Age-Specific Anti-Müllerian Hormone Values and Antral Follicle Count for Women of the Arabian Peninsula - Frontiers, accessed June 16, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.735116/full
Age-Stratified Anti-Müllerian Hormone (AMH) Nomogram: A Comprehensive Cohort Study including 22.920 Women - Frontiers, accessed June 16, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1612194/abstract
Anti-Mullerian Hormone (AMH) Test: Purpose, Levels & Results, accessed June 16, 2025, https://my.clevelandclinic.org/health/diagnostics/22681-anti-mullerian-hormone-test
Anti-Müllerian Hormone (AMH): What Your Levels Can Tell You - Healthline, accessed June 16, 2025, https://www.healthline.com/health/fertility/amh
Ethnicity/Race and Age-Specific Variations of Serum AMH in Women—A Review - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7900163/
Morphological assessment of oocyte quality during assisted reproductive technology cycle - Serval, accessed June 16, 2025, https://serval.unil.ch/resource/serval:BIB_660F1660B2F8.P001/REF.pdf
Oocyte Grading by Morphological Evaluation (Chapter 19 ..., accessed June 16, 2025, https://www.cambridge.org/core/books/principles-of-ivf-laboratory-practice/oocyte-grading-by-morphological-evaluation/C7F6E6F1201C51CD7B667627FA848F35
Oocytes Quality Assessment—The Current Insight: A Systematic Review - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11673492/
Intra- and inter-observer analysis in the morphological assessment ..., accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2761923/
Intra- and inter-observer analysis in the morphological assessment of early-stage embryos, accessed June 16, 2025, https://www.periodicos.capes.gov.br/index.php/acervo/buscador.html?task=detalhes&id=W2171993134
Machine Learning Empowering Personalized Medicine: A Comprehensive Review of Medical Image Analysis Methods - MDPI, accessed June 16, 2025, https://www.mdpi.com/2079-9292/12/21/4411
Artificial Intelligence for Medical Image Analysis: A Guide for Authors and Reviewers | AJR, accessed June 16, 2025, https://ajronline.org/doi/10.2214/AJR.18.20490
Medical image analysis using deep learning algorithms - Frontiers, accessed June 16, 2025, https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2023.1273253/full
Review and Prospect: Artificial Intelligence in Advanced Medical Imaging - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10365109/
Visual Transformer for Object Detection - arXiv, accessed June 16, 2025, https://arxiv.org/pdf/2206.06323
A Survey on Visual Transformer - arXiv, accessed June 16, 2025, http://arxiv.org/pdf/2012.12556
Global Context Vision Transformers - arXiv, accessed June 16, 2025, https://arxiv.org/pdf/2206.09959
(PDF) Vision Transformers in Medical Imaging: a Comprehensive Review of Advancements and Applications Across Multiple Diseases - ResearchGate, accessed June 16, 2025, https://www.researchgate.net/publication/390372350_Vision_Transformers_in_Medical_Imaging_a_Comprehensive_Review_of_Advancements_and_Applications_Across_Multiple_Diseases
Ultrasound Image Analysis with Vision Transformers—Review - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10931322/
Transformers in medical image segmentation: a narrative review - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10722011/
Vision Transformers in Medical Imaging: a Comprehensive Review of Advancements and Applications Across Multiple Diseases - PubMed, accessed June 16, 2025, https://pubmed.ncbi.nlm.nih.gov/40164818/?utm_source=Firefox&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PIb741EQUe6dKnJI51Z8toUeZGRyPMT6zC0ZDzXWlJ0rfmQjj&fc=20240423223220&ff=20250403000316&v=2.18.0.post9+e462414
Vision Transformers in Medical Imaging: a Comprehensive Review ..., accessed June 16, 2025, https://pubmed.ncbi.nlm.nih.gov/40164818/
Enhancing medical image segmentation with a multi-transformer U-Net - PeerJ, accessed June 16, 2025, https://peerj.com/articles/17005/
Systematic Review of Hybrid Vision Transformer Architectures for ..., accessed June 16, 2025, https://pubmed.ncbi.nlm.nih.gov/39871042/
In-depth mining of clinical data: the construction of clinical prediction ..., accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6989986/
Predictive modelling - Wikipedia, accessed June 16, 2025, https://en.wikipedia.org/wiki/Predictive_modelling
Chapter 12 Parametric Survival Analysis | Data Analysis in Medicine and Health using R, accessed June 16, 2025, https://bookdown.org/drki_musa/dataanalysis/parametric-survival-analysis.html
Developing clinical prediction models: a step-by-step guide - The BMJ, accessed June 16, 2025, https://www.bmj.com/content/386/bmj-2023-078276
Parametric regression model for survival data: Weibull regression model as an example - Zhang - Annals of Translational Medicine, accessed June 16, 2025, https://atm.amegroups.org/article/view/11446/html
Parametric Survival Models for Predicting the Benefit of Adjuvant Chemoradiotherapy in Gallbladder Cancer - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3041378/
Individualized Prediction of Breast Cancer Survival Using Flexible Parametric Survival Modeling: Analysis of a Hospital-Based National Clinical Cancer Registry - MDPI, accessed June 16, 2025, https://www.mdpi.com/2072-6694/13/7/1567
What Number of Oocytes Is Appropriate for Defining Poor Ovarian Response? - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4329362/
Defining Low Prognosis Patients Undergoing Assisted ... - Frontiers, accessed June 16, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2018.00461/full
The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists - Frontiers, accessed June 16, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00814/full
Ovarian Stimulation in Assisted Reproductive Technology Cycles for Varied Patient Profiles: An Indian Perspective, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9345274/
Advanced Maternal Age (AMA) - CREOGS Over Coffee, accessed June 16, 2025, https://creogsovercoffee.com/notes/2023/3/19/advanced-maternal-age-ama
Obstetric Care Consensus #11, Pregnancy at age 35 years or older - Novi AMS, accessed June 16, 2025, https://assets.noviams.com/novi-file-uploads/smfm/Publications_and_Guidelines/Joint_Documents/ACOG_SMFM_OCC__11_Pregnancy_at_age_35_years_or_older.pdf
Advanced Maternal Age: Pregnancy After 35 - Cleveland Clinic, accessed June 16, 2025, https://my.clevelandclinic.org/health/diseases/22438-advanced-maternal-age
Culturing surplus poor-quality embryos to blastocyst stage have ..., accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4248145/
How Many Eggs Are Needed for Successful IVF? | RMA - Reproductive Medicine Associates, accessed June 16, 2025, https://rmanetwork.com/blog/number-of-eggs-good-ivf-in-vitro-fertilization/
Percentage of Blastulation on the Number and Function of Meta- phase II Oocytes - JBRA Assisted Reproduction, accessed June 16, 2025, https://www.jbra.com.br/trab/pub/download_trabalho.php?fileSource=/var/www/vhosts/jbra.com.br/media/trab/arq_408&fileName=1130.pdf&id_trabalho=208
Embryo blastulation and quality between days 5 and 6 of extended embryo culture - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8417162/
The Blastulation Rate as a Metric For an In Vitro Fertilization L, accessed June 16, 2025, https://www.longdom.org/open-access/the-blastulation-rate-as-a-metric-for-an-in-vitro-fertilization-laboratorypatient-and-physician-factors-may-impact-that-rate-90412.html
Understanding the Mann-Whitney U-Test - Statistics Solutions, accessed June 16, 2025, https://www.statisticssolutions.com/free-resources/directory-of-statistical-analyses/mann-whitney-u-test-2/
datatab.net, accessed June 16, 2025, https://datatab.net/tutorial/mann-whitney-u-test#:~:text=The%20Mann%2DWhitney%20U%2DTest,t%2Dtest%20for%20independent%20samples.
When to Use the Mann-Whitney U Test - Statistics Solutions, accessed June 16, 2025, https://www.statisticssolutions.com/free-resources/directory-of-statistical-analyses/mann-whitney-u-test/
Computation of Effect Sizes - Psychometrica, accessed June 16, 2025, https://www.psychometrica.de/effect_size.html
Effect Size Calculators, accessed June 16, 2025, https://lbecker.uccs.edu/
T-test Effect Size using Cohen's d Measure : Excellent Tutorial ..., accessed June 16, 2025, https://www.datanovia.com/en/lessons/t-test-effect-size-using-cohens-d-measure/
Weighing The Pros And Cons of PGT-A - Audubon Fertility, accessed June 16, 2025, https://www.audubonfertility.com/post/pros-and-cons-of-pgt-a
Preimplantation Genetic Testing (PGT) in ART - Esco Medical, accessed June 16, 2025, https://www.esco-medical.com/news/preimplantation-genetic-testing-pgt-in-art
A systematic review and meta-analysis of the diagnostic accuracy after preimplantation genetic testing for aneuploidy - PubMed, accessed June 16, 2025, https://pubmed.ncbi.nlm.nih.gov/40367147/
Cost-effectiveness of IVF with PGT-M/A to prevent transmission of spinal muscular atrophy in offspring of carrier couples - PMC - PubMed Central, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10224878/
Does in vitro fertilization (IVF) treatment provide good value for money? A cost-benefit analysis - Frontiers, accessed June 16, 2025, https://www.frontiersin.org/journals/global-womens-health/articles/10.3389/fgwh.2023.971553/full
Non-Invasive Preimplantation Genetic Testing - MDPI, accessed June 16, 2025, https://www.mdpi.com/2073-4425/16/5/552
(PDF) Comparing cost sensitive classifiers by the false-positive to ..., accessed June 16, 2025, https://www.researchgate.net/publication/370984464_Comparing_cost_sensitive_classifiers_by_the_false-positive_to_false-_negative_ratio_in_diagnostic_studies
Clinical Decision Support Software Frequently Asked Questions ..., accessed June 16, 2025, https://www.fda.gov/medical-devices/software-medical-device-samd/clinical-decision-support-software-frequently-asked-questions-faqs
FDA's evolving regulatory framework for AI use in drug & device clinical trials and research, accessed June 16, 2025, https://www.hoganlovells.com/en/publications/fdas-evolving-regulatory-framework-for-ai-use-in-drug-device-clinical-trials-and-research
Navigating US Regulation of Artificial Intelligence in Medicine—A Primer for Physicians, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11975648/
Clinical Decision Support Software; Guidance for Industry and Food and Drug Administration Staff; Availability - Federal Register, accessed June 16, 2025, https://www.federalregister.gov/documents/2022/09/28/2022-20993/clinical-decision-support-software-guidance-for-industry-and-food-and-drug-administration-staff
International multicenter validation of AI-driven ultrasound detection ..., accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11750711/
External validation of an artificial intelligence model using clinical variables, including ICD-10 codes, for predicting in-hospital mortality among trauma patients: a multicenter retrospective cohort study - PubMed, accessed June 16, 2025, https://pubmed.ncbi.nlm.nih.gov/39775076/
FDA AI Guidance - A New Era for Biotech, Diagnostics and Regulatory Compliance, accessed June 16, 2025, https://www.duanemorris.com/alerts/fda_ai_guidance_new_era_biotech_diagnostics_regulatory_compliance_0225.html
Artificial Intelligence for Drug Development - FDA, accessed June 16, 2025, https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/artificial-intelligence-drug-development
AI education for clinicians - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11667627/
AI for Healthcare | Berkeley Exec Ed, accessed June 16, 2025, https://executive.berkeley.edu/programs/ai-healthcare-program
Leading AI Innovation in Health Care - Overview | HMS Postgraduate Education, accessed June 16, 2025, https://postgraduateeducation.hms.harvard.edu/certificate-programs/leading-ai-innovation-health-care
AI in Health Care: 7 Principles of Responsible Use | Kaiser ..., accessed June 16, 2025, https://about.kaiserpermanente.org/news/ai-in-health-care-7-principles-of-responsible-use
The 4 principles of responsible AI in medicine - The World Economic Forum, accessed June 16, 2025, https://www.weforum.org/stories/2025/01/the-4-principles-of-responsible-ai-in-medicine/
Designer Babies? The Ethical and Regulatory Implications of Polygenic Embryo Screening, accessed June 16, 2025, https://petrieflom.law.harvard.edu/2024/03/11/designer-babies-the-ethical-and-regulatory-implications-of-polygenic-embryo-screening/
Non-invasive prenatal testing: ethical issues - Nuffield Council on Bioethics, accessed June 16, 2025, https://www.nuffieldbioethics.org/publication/non-invasive-prenatal-testing-ethical-issues/
The First Baby Born After Polygenic Embryo Screening | Voices in Bioethics, accessed June 16, 2025, https://journals.library.columbia.edu/index.php/bioethics/article/view/9467
Screening embryos for polygenic disease risk: a review of epidemiological, clinical, and ethical considerations | Human Reproduction Update | Oxford Academic, accessed June 16, 2025, https://academic.oup.com/humupd/article/30/5/529/7684172
